Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Kurt Huber is active.

Publication


Featured researches published by Kurt Huber.


Open Heart | 2016

Systematic screening for cardiovascular risk at pharmacies

Miklos Rohla; Heinz Haberfeld; Helmut Sinzinger; Harald Kritz; Maximilian Tscharre; Matthias K. Freynhofer; Kurt Huber; Thomas W. Weiss

Background Early identification and treatment of cardiovascular risk factors (CVRFs) is essential to prevent excess morbidity, mortality and healthcare-related costs. We sought to investigate whether an active screening programme at pharmacies could identify a significant proportion of patients with previously undetected CVRFs. Methods and results Between April and July 2013, 184 pharmacies in Lower Austria enrolled a total of 6800 participants, in whom body mass index (BMI), blood pressure (BP), total cholesterol and blood glucose were measured. Mean age was 58±17u2005years and 67.8% were women. 21% of men and 16% of women had a BMI≥30u2005kg/m2. The crude prevalence of diabetes mellitus (DM) was 7%, hypercholesterolaemia was identified in 57%, and 44% had elevated BP. Among fasting individuals (n=1814), DM was found in 18%. In total, 30% were confronted with a CVRF they were previously unaware of, and pharmacists recommended 45% of all participants to actively consult a physician. A first-time diagnosis of a CVRF was most frequent in the age groups between 25 and 64 (32% of participants). Conclusions This pharmacy-based approach for cardiovascular risk screening found similar overall prevalences of CVRFs as reported by national surveys, but revealed underdiagnoses, particularly in lower age groups. A previously unknown CVRF was identified in every third individual, frequently prompting the pharmacists to recommend the consultation of a physician. An active screening approach at pharmacies might therefore serve as an effective alternative to the public preventive medical examination, particularly in younger age groups.


CME | 2012

Aktuelles in puncto Blutverdünnung

Thomas Höchtl; Serdar Farhan; Kurt Huber

ZusammenfassungAntikoagulanzien werden standardmäßig bei Patienten mit akutem Koronarsyndrom oder Vorhofflimmern eingesetzt. In den letzten Jahren wurden zahlreiche neue Substanzen entwickelt und in klinischen Studien überprüft. Das Paradigma lautet dabei, dass diese Neuentwicklungen nicht nur die ischämischen oder thromboembolischen Ereignisse reduzieren sollen. Vielmehr soll vor allem die Rate an Blutungskomplikationen sinken. Die wichtigsten Substanzen sind derzeit Bivalirudin, Fondaparinux, Rivaroxaban, Apixaban und Dabigatran. Aktuell sind im deutschsprachigen Raum Rivaroxaban und Dabigatran für die Prävention von Schlaganfällen und systemischen Embolien bei nichtvalvulärem Vorhofflimmern zugelassen.


Archive | 2014

Testing Drug Eluting Paclitaxel Balloon Valvuloplasty in an Experimental Model of Aortic Stenosis

Konstantinos Spargias; Mariann Gyöngyösi; Rayyan Hemetsberger; Anikó Pósa; Noemi Pavo; Imre Pavo; Kurt Huber; Zsolt Petrasi; Örs Petneházy; Rembert Pogge von Strandmann; Jeffrey Park; Dietmar Glogar; Gerald Maurer; Nalini M. Rajamannan

Balloon aortic valvuloplasty (BAV) was introduced in 1986 as an alternative non- surgical therapeutic option in elderly and high-risk patients with aortic stenosis [1]. It generates small to moderate increase in the effective aortic valve area (AVA) and decline in the transvalvular pressure gradient (by average 50 %) which results in early symptomatic improvements in the majority of patients [2–5]. Nonetheless, clinical data demonstrates restenosis rates of the aortic valve occurring up to 83 % observed at 6 months and is almost universal within 1 year after the procedure [3, 6, 7]. Restenosis promptly revokes the improvement in symptoms and quality of life, which is so much valued especially in the elderly population with multiple comorbidities and limited life expectancy. The initial enthusiasm about BAV led to its more liberal use in high-risk patients but registry data indicated that it does not alter the natural history of aortic stenosis [8].


American Heart Journal | 2007

Effect of timing of clopidogrel administration on 30-day clinical outcomes: 300-mg loading dose immediately after coronary stenting versus pretreatment 6 to 24 hours before stenting in a large unselected patient cohort

Tibor Szük; Mariann Gyöngyösi; Nóra Homoródi; Eva Kristof; Csaba Kiraly; István Édes; Andrea Facskó; Noemi Pavo; Gottfried Sodeck; Christoph Strehblow; Serdar Farhan; Gerald Maurer; Dietmar Glogar; Hans Domanovits; Kurt Huber


Archive | 2015

acute phase of myocardial infarction Insufficient secretion of atrial natriuretic peptide at

Takeshi Kamijo; Masahiko Kinoshita; Takayoshi Tsutamoto; Naoko Mabuchi; Mariann Gyöngyösi; Georg Geyer; Johann Wojta; Kurt Huber; Rudolf Jarai; Nelly Iordanova; Róbert Járai; Annamaria Raffetseder; Wolfgang Woloszczuk


/data/revues/00029149/unassign/S0002914914000381/ | 2014

Influence of High-Dose Highly Efficient Statins on Short-Term Mortality in Patients Undergoing Percutaneous Coronary Intervention With Stenting for Acute Coronary Syndromes

Ioannis Tentzeris; Miklos Rohla; Rudolf Jarai; Serdar Farhan; Matthias K. Freynhofer; Gerhard Unger; Michael Nürnberg; Alexander Geppert; Emil Wessely; Johann Wojta; Kurt Huber


Archive | 2013

mast cells and basophils C5a stimulates production of plasminogen activator inhibitor-1 in human

Gerald Maurer; Kurt Huber; Peter Valent; Wolfgang R. Sperr; Gerhard Fritsch; Dieter Printz; Bernd R. Binder; Georg Schatzl; Joerg Zwirner; Johann Wojta; Christoph Kaun; Gerlinde Zorn; Minoo Ghannadan; Alexander W. Hauswirth


Archive | 2012

ConfliC t of interest poliCies and dis Closure requirements among european s oCiety of Cardiology national Cardiovas Cular journals

Fernando Alfonso; Adam Timmis; Fausto Pinto; Giuseppe Ambrosio; Hugo Ector; Loizos Antoniades; Mansoor Ahmad; Eduard Apetrei; Kaduo Arai; Jean-Yves Artigou; Michael Aschermann; Michael Böhm; Leonardo Bolognese; Raffaele Bugiardini; Ariel Cohen; István Édes; Joseph Elias; Javier Galeano; Habib Haouala; Magda Heras; Christer Höglund; Kurt Huber; Ivan Hulín; Mario Ivanusa; Chi-Tai Kuo; Chu-Pak Lau; Victor A. Lyusov; Manlio F. Márquez; Izet Masic; Luiz Felipe


/data/revues/00028703/v144i3/S0002870302001084/ | 2011

High-sensitivity C-reactive protein in the prediction of coronary events in patients with premature coronary artery disease

W. Speidl; Senta Graf; Stefan Hornykewycz; Mariam Nikfardjam; Alexander Niessner; Gerlinde Zorn; Johann Wojta; Kurt Huber


Archive | 2010

sterreichische Zentren 2010/2011 Datenverantwortlicher *) Jahr der Monitorvisiten bzw. des Audits

Georg Grimm; Heinz Sochor; Dietmar Glogar; Innere Medizin; Josef Aichinger; Helmut Brussee; Burkert Pieske; Günter Heyer; Heinz Koller; H. Krappinger; Krankenhaus Rudolfstiftung; Franz Weidinger; Werner Benzer; Georg Gaul; Ana Mar oa; Gerhard Bonner; Helmut D. Glogar; Norbert Muzika; Hubert Wallner; Martin Klicpera; Max Pichler; Gerald Zenker; Klaus Kaspar; Kurt Huber; Peter Siostrzonek; Dieter Brandt; G. Obermayer; Karl Silberbauer; Bernd Eber; Krankenhaus der Stadt Krems

Collaboration


Dive into the Kurt Huber's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Dietmar Glogar

Medical University of Vienna

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Rudolf Jarai

Medical University of Vienna

View shared research outputs
Top Co-Authors

Avatar

Serdar Farhan

Icahn School of Medicine at Mount Sinai

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge